> Pharmaceutical Litigation > Zometa
Zometa belongs to a group of drugs called bisphosphonates. It is prescribed to cancer patients to treat hypercalcemia, or high blood levels of calcium. Zometa is administered intravenously. Approved by the Food and Drug Administration in 2001, Zometa has also been implicated in preventing the relapse of breast cancer, although studies have yielded inconclusive results.
During a study examining the results of Zometa on breast cancer relapse prevention, 26 women (1-2% of the study group) experienced osteonecrosis, or bone death. Osteonecrosis mainly affects the jawbone, and it prevents the healing of jaw tissue after minor trauma like dental work. Osteonecrosis of the jaw (ONJ) is a painful and debilitating condition that can lead to infection or fracture and may require surgery.
ONJ has long been associated with bisphosphonates, and yet patients receive little to no warning about the risk before being given Zometa. If you or a loved one has suffered from osteonecrosis, the attorneys at the Law Offices of Brian D. Witzer can help. You deserve justice and compensation.
Please contact us today by calling (888) WITZER-6 for a free, no-obligation consultation.